iBio Posts $33M FY26 Loss, Advances Obesity Pipeline with $88M Cash
IBIO sits 88% above its 52-week low of $0.76.
Summary
iBio reported fiscal 2026 results with a net loss of $33.0 million, up from $18.4 million last year, driven by a $11.3 million increase in R&D spending to $19.6 million. The company ended the year with $88.0 million in cash and investments, extending its runway into fiscal 2028. Pipeline progress includes completing the single ascending dose portion of the IBIO-600 Phase 1 trial with no safety issues, advancing IBIO-610 into IND-enabling studies, and moving IBIO-800 into IND-enabling development. The company also in-licensed AstralBio's amylin receptor antibody program and closed a $26 million private placement in January. This follows the August 2025 public offering and the recent proxy seeking to double authorized shares, indicating continued capital needs despite the strengthened balance sheet.
At the time of this announcement, IBIO was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $69.5M. The 52-week trading range was $0.76 to $3.82. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.